When Reviewers Change, CDRH Science Council Seeks Smoother Transitions
This article was originally published in The Gray Sheet
Executive Summary
The CDRH center science council is developing policies to help ensure smoother transitions when a review team changes during pre-market device reviews.
You may also be interested in...
Regulatory News In Brief
FDA releases de novo guidance
Regulatory News In Brief
FDA releases de novo guidance
Shuren: New Clinical Trial Guidelines In The Works
FDA device center director Jeffrey Shuren says new guidance documents coming down the pike will clarify issues related to clinical trial design and approval.